Fellow Nurses Africa | Lagos, Nigeria | 11 December, 2025
Canada has made a major breakthrough in maternal mental health with the approval of Zurzuvae (zuranolone), the first oral medication specifically developed to treat postpartum depression (PPD).
The newly approved drug is a once-daily pill taken for 14 days, and clinical trials show it can start relieving symptoms in as little as three days, a significant improvement compared to traditional antidepressants that often take weeks.
Unlike older treatments such as SSRIs or the IV-only brexanolone infusion, Zurzuvae can be taken at home, reducing hospital visits and giving new mothers a more convenient option during a vulnerable period.
PPD affects 1 in 5 women, yet existing treatments were not originally designed for the condition. Zurzuvae changes that. It works by targeting GABA-A receptors, a brain pathway linked to mood regulation affected by hormonal shifts after childbirth.
However, access and affordability remain key questions. Early reports suggest the cost may be high, and coverage by private insurers and provincial plans will determine how widely mothers can benefit from it.
This approval marks a historic step forward in addressing postpartum depression with treatments designed specifically for the condition.
